ReP USP - Resultado da busca

Artigo de periodico
Living donor liver transplantation: 35 years of saving lives (2024)
Raia, Silvano Mario Attilio ; Seda Neto, Joao
Source: LANCET. Unidade: FM
Subjects: TRANSPLANTE DE FÍGADO, DOAÇÃO ENTRE VIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAIA, Silvano Mario Attilio e SEDA NETO, Joao. Living donor liver transplantation: 35 years of saving lives. LANCET, v. 403, n. 10427, p. 614-615, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58719. Acesso em: 26 jan. 2026.
APA
Raia, S. M. A., & Seda Neto, J. (2024). Living donor liver transplantation: 35 years of saving lives. LANCET, 403( 10427), 614-615. doi:10.1016/S0140-6736(23)01889-5
NLM
Raia SMA, Seda Neto J. Living donor liver transplantation: 35 years of saving lives [Internet]. LANCET. 2024 ; 403( 10427): 614-615.[citado 2026 jan. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58719
Vancouver
Raia SMA, Seda Neto J. Living donor liver transplantation: 35 years of saving lives [Internet]. LANCET. 2024 ; 403( 10427): 614-615.[citado 2026 jan. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58719
Artigo de periodico
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 (2023)
Ong, Kanyin Liane; Stafford, Lauryn K.; Mclaughlin, Susan A.; Boyko, Edward J.; Vollset, Stein Emil; Smith, Amanda E.; Dalton, Bronte E.; Duprey, Joe; Cruz, Jessica A.; Hagins, Hailey; Benseñor, Isabela Judith Martins
Source: LANCET. Unidade: FM
Subjects: DIABETES MELLITUS, FATORES DE RISCO, AUTOCUIDADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ONG, Kanyin Liane et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. LANCET, v. 402, n. 10397, p. 203-234, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57874. Acesso em: 26 jan. 2026.
APA
Ong, K. L., Stafford, L. K., Mclaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., et al. (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. LANCET, 402( 10397), 203-234. doi:10.1016/S0140-6736(23)01301-6
NLM
Ong KL, Stafford LK, Mclaughlin SA, Boyko EJ, Vollset SE, Smith AE, Dalton BE, Duprey J, Cruz JA, Hagins H, Benseñor IJM. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 [Internet]. LANCET. 2023 ; 402( 10397): 203-234.[citado 2026 jan. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57874
Vancouver
Ong KL, Stafford LK, Mclaughlin SA, Boyko EJ, Vollset SE, Smith AE, Dalton BE, Duprey J, Cruz JA, Hagins H, Benseñor IJM. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 [Internet]. LANCET. 2023 ; 402( 10397): 203-234.[citado 2026 jan. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57874
Artigo de periodico
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (2023)
Rovin, Brad H; Barratt, Jonathan; Heerspink, Hiddo J. L.; Alpers, Charles E.; Bieler, Stewart; Chae, Dong-Wan; Diva, Ulysses A.; Floege, Juergen; Gesualdo, Loreto; Inrig, Jula K.; Noronha, Irene de Lourdes
Source: LANCET. Unidade: FM
Subjects: ANGIOTENSINAS, GLOMERUNEFRITE, INSUFICIÊNCIA RENAL CRÔNICA, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROVIN, Brad H et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. LANCET, v. 402, n. 10417, p. 2077-2090, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57858. Acesso em: 26 jan. 2026.
APA
Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D. -W., et al. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. LANCET, 402( 10417), 2077-2090. doi:10.1016/S0140-6736(23)02302-4
NLM
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, Diva UA, Floege J, Gesualdo L, Inrig JK, Noronha I de L. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [Internet]. LANCET. 2023 ; 402( 10417): 2077-2090.[citado 2026 jan. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57858
Vancouver
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, Diva UA, Floege J, Gesualdo L, Inrig JK, Noronha I de L. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [Internet]. LANCET. 2023 ; 402( 10417): 2077-2090.[citado 2026 jan. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57858

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies